Table 6.

Novel agents in clinical trials

Study Agents	Other agents	Disease	Dosage	Clinical trails	No Pts	Response	Reference
CPX-351 (liposomal cytarabine: daunorubicin at 5:1)		Elderly untreated AML	100 u/m2 D1,3,5	Phase IIb	45	acceptable toxicity and comparable to standard regimen	[9]
Voreloxin (anticancer quinolone derivative)		Elderly untreated AML	72 mg/m2 qw × 3	Phase II	105	CR/CRp: 47%	[45]
Amonafide (AS1413)	Cytarabine	Secondary AML	600 mg/m2/d IV d1-5	Phase II	88	CR/CRi: 42%	[46]
behenoylara-C	Idarubicin Etoposide	untreated AML	300-350 mg/m2 × 10d	Phase II	165	CR: 87%	[47]
Lenalidomide	Cytarabine, Daunorubicin	5q-AML/MDS	10 mg/d po d1-21	Phase I/II	18	CR/CRi: 47%	[50]
Ribavirin	Cytarabine	AML			13	CR:7%	[51]
ARRY-520	idarubicin	refractory AML	0.8-5.6 mg/m2 IV	Phase I	33	MTD: 4.5 mg/m2	[52]
AZD1152		relapsed AML	50 mg-1600 mg	Phase I/II	64	MTD: 1200 mg	[53]
AZD6244		AML	100 mg po bid	Phase II	47	Feasible treatment	[56]
Terameprocol		relapsed and refractory AML	1000-2200 mg iv, 3/w, ×2-3w	Phase I/II	16	MTD: 1500 mg	[57]

Abbreviations: CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; MTD: maximal tolerated dose;